Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction Diabetes Technology & Therapeutics 2010; 12:49-55.
Rosenstock J, Bergenstal R, DeFronzo RA, et. al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008; 31: 2177-2182.
Boss AH, Yu W, Ellerman K. Prandial Insulin; Is inhaled enough? Drug Development Research 2008; 69:138-142.
Rave K, Heise T, Heinemann L, et. Al. Inhaled Technosphere® insulin in comparision to subcutaneous regular human insulin: Time action profile and variability in subjects with type 2 diabetes. Journal of Diabetes Science and Technology 2008; 2:205:212.
Tack CJ, Christov V, deGalan BE, et. al. Randomized forced titration to different doses of Technosphere® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci ence and Technol 2008; 2:47-57.
Rave K, Pfuetzner A, Heise T, et. al. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes, Diabetes Care 2007; 30: 2307-2308.
Richardson PC and Boss AH. Technosphere® insulin technology. Diabetes Technology & Therapeutics 2007; 9: S65-S72.
.jpg "Recent Publications about AFREZZA™ | Mannkindcorp.com")
